Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-04-12

Clinical Trial Update: A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia [Phase 3]

View source ↗

Summary

Phase 3 study evaluating transition from zolpidem to lemborexant for insomnia has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lemborexant (lemborexant)
  • Zolpidem (zolpidem)

Snippet

Sponsor: Eisai Inc. | Conditions: Insomnia | Phase 3 | Status: COMPLETED | Results posted: 2021-04-12